MARKET

ACHV

ACHV

Achieve Life Sciences Inc
NASDAQ
5.30
+0.52
+10.88%
Pre Market: 5.50 +0.2 +3.75% 08:09 05/29 EDT
OPEN
4.800
PREV CLOSE
4.780
HIGH
5.37
LOW
4.695
VOLUME
10.98K
TURNOVER
0
52 WEEK HIGH
6.15
52 WEEK LOW
2.000
MARKET CAP
544.09M
P/E (TTM)
-4.7628
1D
5D
1M
3M
1Y
5Y
1D
ACHIEVE APPOINTS VETERAN BANKING EXECUTIVE JOHN DAVIS AS CHIEF CREDIT OFFICER
Reuters · 1d ago
Weekly Report: what happened at ACHV last week (0518-0522)?
Weekly Report · 4d ago
Analysts Conflicted on These Healthcare Names: InMode (INMD), Achieve Life Sciences (ACHV) and BioNTech SE (BNTX)
TipRanks · 05/21 11:20
Achieve Life Sciences Unveils 52 Week Safety Data Of Cytisinicline Ahead Of FDA Decision
NASDAQ · 05/20 06:56
Achieve Life Sciences reports 52-week cytisinicline trial shows no new safety signals
PUBT · 05/19 18:15
Achieve Life Sciences Presents Safety Data from 52 Weeks of Continuous Cytisinicline Treatment
Barchart · 05/19 13:15
Weekly Report: what happened at ACHV last week (0511-0515)?
Weekly Report · 05/18 09:17
Achieve Life Sciences director Martin Christopher Nathan files initial beneficial ownership statement
PUBT · 05/13 20:29
More
About ACHV
Achieve Life Sciences, Inc. is a late-stage specialty pharmaceutical company. The Company focuses on addressing the global smoking health and nicotine dependence epidemic through the development and commercialization of cytisinicline. It has completed two Phase III studies with cytisinicline for smoking cessation and one Phase II study with cytisinicline in vaping cessation. Cytisinicline is a naturally occurring, plant-based alkaloid. Cytisinicline is structurally similar to nicotine and has a dual-acting mechanism of action, being both a receptor agonist and antagonist. Cytisinicline is an investigational product candidate being developed for the treatment of nicotine dependence and has not been approved by the Food and Drug Administration for any indication in the United States. Cytisinicline acts as a partial agonist/antagonist, binding to alpha-4 beta-2 nicotinic receptors in the brain and is thought to have two potential consequences in treating nicotine dependence.

Webull offers Achieve Life Sciences Inc stock information, including NASDAQ: ACHV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ACHV stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ACHV stock methods without spending real money on the virtual paper trading platform.